AbbVie | ABBV

Stock Price
167.20
Daily Change
-0.81 -0.48%
Monthly
-6.69%
Yearly
3.34%
Q2 Forecast
178.62
Peers Price Chg Day Year Date
4523 Eisai 6,240.00 -19.00 -0.30% -19.52% Apr/26
ABBV AbbVie 167.20 -0.81 -0.48% 3.34% Apr/25
ABT Abbott 106.90 -0.06 -0.06% -1.70% Apr/25
ALKS ALKERMES 24.44 0.37 1.52% -13.90% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
AZN AstraZeneca 11,972.00 -54.00 -0.45% 1.49% Apr/26
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMRN BioMarin Pharmaceutical 82.17 -9.07 -9.94% -11.65% Apr/25
BMY Bristol-Myers Squibb 44.70 -4.16 -8.51% -34.28% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
GSK GlaxoSmithKline 1,636.25 -4.25 -0.26% 13.87% Apr/26
JNJ J&J 146.84 -1.73 -1.16% -9.70% Apr/25
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
MDT Medtronic 79.06 -1.21 -1.50% -12.13% Apr/25
MRK Merck 130.49 3.59 2.83% 15.04% Apr/25
NBIX Neurocrine Biosciences 137.73 -1.24 -0.89% 34.08% Apr/25
NOVN Novartis 89.35 -0.65 -0.72% -2.19% Apr/26
PCRX Pacira 25.50 -0.40 -1.54% -42.14% Apr/25
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PRGO Perrigo 31.26 0.03 0.10% -13.28% Apr/25
RARE Ultragenyx Pharmaceutical 43.85 -0.41 -0.93% 3.59% Apr/25
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
ROG Roche Holding 219.35 0.55 0.25% -20.58% Apr/26
SAN Sanofi 89.91 -1.71 -1.87% -11.70% Apr/26
UCB UCB 122.55 -2.55 -2.04% 43.27% Apr/26
UTHR United Therapeutics 235.98 -1.02 -0.43% 4.48% Apr/25
VRTX Vertex Pharmaceuticals 397.24 -3.35 -0.84% 22.87% Apr/25
ZTS Zoetis 153.44 2.51 1.66% -11.28% Apr/25

Indexes Price Day Year Date
SPX US500 5083 -23.21 -0.46% 22.92% Apr/26

AbbVie traded at $167.20 this Thursday April 25th, decreasing $0.81 or 0.48 percent since the previous trading session. Looking back, over the last four weeks, AbbVie lost 6.69 percent. Over the last 12 months, its price rose by 3.34 percent. Looking ahead, we forecast AbbVie to be priced at 178.62 by the end of this quarter and at 168.58 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.